IMVT

Immunovant, Inc.

40.29 USD
+1.27 (+3.25%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Immunovant, Inc. stock is up 16.45% since 30 days ago. The next earnings date is Feb 2, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 80% of the previous 4 December’s closed higher than November. In the last 10 Unusual Options Trades, there were 9 CALLs, 1 PUT. 100% of analysts rate it a buy.

Options Flow Last 10
Date & Time Expiration Date Strike Price Trade Type Size Open Interest
30 Nov 15:44 15 Dec, 2023 25.00 CALL 18 2532
30 Nov 15:44 15 Dec, 2023 25.00 CALL 34 2532
01 Dec 17:14 15 Dec, 2023 40.00 CALL 200 3258
01 Dec 17:19 15 Dec, 2023 40.00 CALL 800 3258
01 Dec 17:33 19 Jan, 2024 40.00 CALL 132 1970
04 Dec 17:01 15 Dec, 2023 40.00 CALL 179 2033
05 Dec 19:35 19 Apr, 2024 50.00 CALL 1000 86
05 Dec 19:56 16 Jan, 2026 40.00 PUT 127 212
06 Dec 14:52 19 Jan, 2024 40.00 CALL 316 1877
06 Dec 14:53 19 Jan, 2024 40.00 CALL 666 1877

About Immunovant, Inc.

Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. IMVT-1401 is in Phase IIa clinical trials for the. treatment of myasthenia gravis and thyroid eye disease. The company is headquartered in New York, New York.

  • UBS
    Fri Dec 1, 13:29
    buy
    confirm
  • Truist Securities
    Wed Nov 15, 11:36
    buy
    confirm